Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus

Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib , its next-generation oral TYK2 inhibitor, in ...

The creator of Claude Code just revealed his workflow, and developers are losing their minds

Claude Code creator Boris Cherny reveals his viral workflow for running multiple AI agents simultaneously—transforming how ...

Nvidia Unveils Alpamayo AI For Autonomous Vehicles: 'Chat-GPT Moment' For Cars

At CES 2026 on Monday, NVIDIA Corp. (NASDAQ:NVDA) unveiled a shift in autonomous vehicle (AV) development with the release of ...

Dave Canales: Panthers can't worry about being underdogs, just have to play our best

The Panthers are 10.5-point underdogs against the Rams in Saturday's playoff opener, and Carolina coach Dave Canales says ...

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer –– Comprehensive ...